ロード中...

Transforming the early drug development paradigm at the National Cancer Institute: The formation of NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN)

Early drug development for cancer requires broad collaboration and skilled clinical investigators to enable enrollment of patients whose tumors have defined molecular profiles. To respond to these challenges, the National Cancer Institute (NCI) transformed its 60-year old early phase drug developmen...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Massett, Holly A., Mishkin, Grace, Moscow, Jeffrey A., Gravell, Amy, Steketee, Michael, Kruhm, Martha, Han, Sae H., Barry, Barbara, Montello, Michael, Zwiebel, James, Abrams, Jeffrey S., Doroshow, James H., Ivy, S. Percy
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891162/
https://ncbi.nlm.nih.gov/pubmed/31439585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1754
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!